Articles Tagged With:
-
Accreditation Program Elevates Pain and Addiction Care in the ED
Long before the COVID-19 pandemic, frontline providers were confronting an epidemic of patients struggling with opioid use disorders (OUD). Recognizing the urgent need for improvement in this area, the American College of Emergency Physicians is rolling out a new accreditation program that is aimed at nudging EDs across the country to up their game when it comes to both the treatment of pain and the way they manage patients who present with OUD.
-
Try Using Telehealth to Diagnose and Manage Patients with Dizziness
Appreciating the need for more guidance in this area, an international task force comprised of physician-scientists from 10 countries developed consensus-based guidelines to help frontline providers diagnose and triage patients with dizziness over a telehealth or virtual platform.
-
Researchers Study the Effects of Intensive Primary Care
A case management-type of model, called primary care intensive management, could provide some limited benefits for more complex patients, research shows. But the research also suggests questions about how population health resources are best spent.
-
Follow-Up Is Crucial but Difficult for Case Managers During Pandemic
The pandemic exacerbated social determinants of health problems for many patients seen by case managers. Case managers had to find new resources for patients, including aid from the CARES Act.
-
As Pandemic Rages, Case Managers Can Focus on Crisis Management
Crisis management is important to case management leaders and their teams as the COVID-19 pandemic continues. COVID-19 cases and hospitalizations sharply increased through the end of 2020.
-
FDA Issues Third COVID-19 Therapeutic EUA This Month
The list of COVID-19 therapeutics is growing rapidly.
-
Nutritional Interventions in Prodromal Alzheimer’s Disease: The 36-Month LipiDiDiet Multinutrient Clinical Trial
In a randomized, double-blind, placebo-controlled trial of Fortasyn Connect (Souvenaid), a nutraceutical drink, patients with prodromal Alzheimer’s disease demonstrated, over a 36-month period, a slower decline in cognitive functions compared to the control group.
-
Disease-Modifying Therapy and Long-Term Disability in Multiple Sclerosis
In a multicenter, observational, retrospective “real world” analysis of a large cohort of relapsing multiple sclerosis (MS) patients, the authors found that being on disease-modifying therapy decreased the risk of long-term disability progression in both pediatric and adult MS patients.
-
Multiple Sclerosis and Vascular Disease
This postmortem study of multiple sclerosis (MS) patients evaluated the presence and pathological significance of extracranial systemic and cerebral small vessel disease in patients with MS compared to healthy controls. MS patients had less systemic vascular disease and more small vessel disease in the brain compared to controls.
-
Sporadic Creutzfeldt-Jakob Disease: A Genome-Wide Association Study
Sporadic Creutzfeldt-Jacob disease (sCJD), the most common form of human prion disease, is characterized as a rapidly fatal neurodegenerative process caused by propagation of a transmissible misfolded prion protein gene (PRNP). However, selective PRNP mutations only account for a small subset of sCJD cases, leading to interest in discovering additional genetic risk factors. Through a two-stage study design using genome-wide association studies, the authors have identified two novel risk loci, STX6 and GAL3ST1, which encode for proteins involved in cellular trafficking of prions and sphingolipid metabolism, respectively. These findings provide insights into sCJD pathogenesis and are an avenue for further research.